By Juan Carlos Rodriguez (January 7, 2014, 4:41 PM EST) -- The Eighth Circuit said Tuesday that Johnson & Johnson's pharmaceutical unit must pay $630,000 to a patient who claimed the company deliberately failed to properly warn consumers of the risks linked to its antibiotic Levaquin, saying there was no misconduct that could justify overturning the award.
Ortho-McNeil-Janssen Pharmaceuticals Inc. had argued to the appeals court that plaintiff John Schedin's expert biostatistician admitted after trial that he had not — as Schedin represented — provided all the information OMJP requested during discovery regarding his relative-risk calculations and supporting data.
The company said if the calculations had been properly disclosed, they would have...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!